Therapy-related acute myeloid leukemia following radioactive iodine treatment for thyroid cancer
Tóm tắt
Therapy-related acute myeloid leukemia (t-AML) associated with radioiodine treatment (RAI) is emerging as an important clinical entity with the rise in incidence of thyroid cancer. We conducted an electronic search of MEDLINE and EMBASE, and also searched reference lists of articles and abstracts from conference proceedings for case reports and review articles on t-AML following radioiodine therapy. A total of 37 patients with acute myeloid neoplasms following radioiodine treatment were analyzed. The median RAI dose was 324 mCi, and median age was 47.5 years with M/F ratio of 1:3. Latency period was 1–4 years, and the median time from RAI exposure to diagnosis of t-AML was 2.9 years. FAB M2 and M3 were the two most common t-AML subtypes reported. Seventy-one percent of the cases that reported cytogenetic abnormalities were classified as unfavorable. The most commonly reported abnormalities were del 5q and t(15:17). Survival outcomes were not reported due to lack of patient-level data. T-AML following radioiodine therapy for thyroid cancer appears to have a shorter latency period than other types of t-AML, which is an important consideration for post-therapy surveillance. Reporting of cases and outcomes will help provide data for further research. Identifying biomarkers that help risk-stratify patients prior to therapy and specific genetic-guided therapies may help improve outcomes.
Tài liệu tham khảo
Iyer NG, Morris LGT, Tuttle RM, Shaha AR, Ganly I (2011) Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117(19):4439–4446. doi:10.1002/cncr.26070
Cancer of the thyroid—SEER stat fact sheets. http://seer.cancer.gov/statfacts/html/thyro.html. Accessed 8 Feb 2015
Sawka AM, Thabane L, Parlea L et al (2009) Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid Off J Am Thyroid Assoc 19(5):451–457. doi:10.1089/thy.2008.0392
Mauritzson N, Albin M, Rylander L et al (2002) Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 16(12):2366–2378. doi:10.1038/sj.leu.2402713
Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T (2004) Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18(1):120–125. doi:10.1038/sj.leu.2403187
Schroeder T, Kuendgen A, Kayser S et al (2012) Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica 97(2):206–212. doi:10.3324/haematol.2011.049114
Bitton R, Sachmechi I, Benegalrao Y, Schneider BS (1993) Leukemia after a small dose of radioiodine for metastatic thyroid cancer. J Clin Endocrinol Metab 77(5):1423–1426. doi:10.1210/jcem.77.5.8077344
Grudeva-Popova J, Yaneva M, Zisov K, Ananoshtev N (2007) Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review. J BUON Off J Balk Union Oncol 12(1):129–132
Gilabert M, Prebet T (2012) Acute leukemia arising after radioiodine treatment for thyroid cancer. Haematologica 97(8):e28–e29. doi:10.3324/haematol.2012.067454
Lee SH, Eom KS, Lee S et al (2006) A case of acute promyelocytic leukemia after iodine-131 treatment for thyroid cancer. Korean J Hematol 41(4):302. doi:10.5045/kjh.2006.41.4.302
Roldán-Schilling V, Fernández Abellán P, Domínguez Escribano JR, Rivas González C, Mut Barberá E, Calatayud Cendra R (1998) Acute leukemias after treatment with radioiodine for thyroid cancer. Haematologica 83(8):767–768
Ankit J, Premalata CS, Saini KS et al (2009) Acute myeloid leukemia following radioactive iodine therapy for papillary carcinoma of the thyroid. Turk J Hematol 26:97–99
Trikalinos NA, Chen Q, Ning Y, Sausville EA, Baer MR (2013) Unbalanced 11;18 translocation in an acute erythroid leukemia after radioactive iodine therapy. Cancer Genet 206(6):252–255. doi:10.1016/j.cancergen.2013.06.003
Laurenti L, Salutari P, Sica S et al (1998) Acute myeloid leukemia after iodine-131 treatment for thyroid disorders. Ann Hematol 76(6):271–272
Jeong JH, Ahn JY, Park SH, Park MJ, Kim KH, Hong JS (2012) A case of therapy-related acute myeloid leukemia with inv(16)(p13.1q22) after single low-dose iodine-131 treatment for thyroid cancer. Korean J Hematol 47(3):225–228. doi:10.5045/kjh.2012.47.3.225
Weingertner AS, Wilt M, Atallah I, Fohrer C, Mauvieux L, Rodier J-F (2009) Myeloid sarcoma of the uterine cervix as presentation of acute myeloid leukaemia after treatment with low-dose radioiodine for thyroid cancer: a case report and review of the literature. Case Rep Oncol 2(1):1–6. doi:10.1159/000191215
Richards EM, Marcus RE (1993) Acute promyelocytic leukaemia following radioiodine therapy. Clin Lab Haematol 15(1):55–58
Takemoto Y, Hata T, Kamino K et al (1995) Leukemia developing after 131I treatment for thyroid cancer in a patient with Werner’s syndrome: molecular and cytogenetic studies. Intern Med 34(9):863–867. doi:10.2169/internalmedicine.34.863
Beierwaltes WH (1981) New horizons for therapeutic nuclear medicine in 1981. J Nucl Med 22(6):549–554
Siemsen JK (1970) Leukemia following cancericidal doses of radioiodine. J Nucl Med 11:400
Blom PS, Querido A, Leeksma CH (1955) Acute leukaemia following x-ray and radioiodine treatment of thyroid carcinoma. Br J Radiol 28(327):165–166
Lahoud OB, Ajay D, Chandra AB. Early occurrence of therapy-related acute myeloid leukemia (t-AML) with monocytic differentiation with trisomy 8 cytogenetic abnormality after radioactive iodine (RAI) treatment for papillary thyroid cancer. Blood J. http://www.bloodjournal.org/content/124/21/5325?sso-checked=true. Accessed 26 May 2015
Delarue J, Tubiana M, Dutreix J (1953) Cancer of the thyroid treated with radioactive iodine; termination by acute leukemia after an important amelioration. Bull Assoc Fr Pour Létude Cancer 40(3):263–271
Seidlin SM, Siegal E, Yalow AA, Melamed S (1956) Acute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinoma. Science 123(3201):800–801
Jelliffe AM, Jones KM (1960) Leukaemia after radioiodine therapy for thyroid cancer. Clin Radiol 11:134–135
Pochin E (1969) Long-term hazards of radioiodine treatment of thyroid carcinoma. In: Hedinger C (ed) Thyroid cancer, vol 12., UICC monograph seriesSpringer, Berlin, pp 293–304
Lewallen CG, Godwin JT (1963) Acute myelogenous leukemia complicating radioactive iodine therapy of thyroid cancer. Report of a case. Am J Roentgenol Radium Ther Nucl Med 89:610–617
Brincker H, Hansen HS, Andersen AP (1973) Induction of leukaemia by 131I treatment of thyroid carcinoma. Br J Cancer 28(3):232–237
Uppin MS, Paul TR, Rajappa S, Gayathri K, Jacob R, Uppin SG (2007) Leukemia as a second malignancy. Indian J Pathol Microbiol 50(3):644–647
Döhner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474. doi:10.1182/blood-2009-07-235358
Smith SM, Le Beau MM, Huo D et al (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102(1):43–52. doi:10.1182/blood-2002-11-3343
Noaparast Z, Hosseinimehr SJ (2013) Radioprotective agents for the prevention of side effects induced by radioiodine-131 therapy. Future Oncol 9(8):1145–1159. doi:10.2217/fon.13.79
Li L, Li M, Sun C et al (2011) Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell 20(5):591–605. doi:10.1016/j.ccr.2011.09.011